Diagnostic utility of a ferritin-to-procalcitonin ratio to differentiate patients with COVID-19 from those with bacterial pneumonia: a multicenter study
…, KM Erlandson, SJ Scherger… - Open Forum …, 2021 - academic.oup.com
Background There is an urgent need for accurate, rapid, inexpensive biomarkers that can
differentiate coronavirus disease 2019 (COVID-19) from bacterial pneumonia. We assess the …
differentiate coronavirus disease 2019 (COVID-19) from bacterial pneumonia. We assess the …
[HTML][HTML] Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: A systematic review and meta …
…, O Samara, A Monzon, G Montalbano, S Scherger… - Cytokine, 2022 - Elsevier
Background Sepsis is a global health challenge associated with significant morbidity and
mortality. Detrimental sepsis effects are attributed to excessive inflammation or a “cytokine …
mortality. Detrimental sepsis effects are attributed to excessive inflammation or a “cytokine …
COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs
…, JJ Montenegro-Idrogo, S Scherger… - Therapeutic …, 2021 - journals.sagepub.com
… use of immunosuppressive drugs - Alfonso J. Rodriguez-Morales, Ranjit Sah, Jose Millan-Oñate,
Angel Gonzalez, Juan … Am J Respir Crit Care Med 2018; 197: 757–767. … Sias Scherger …
Angel Gonzalez, Juan … Am J Respir Crit Care Med 2018; 197: 757–767. … Sias Scherger …
Toxoplasmosis in non‐cardiac solid organ transplant recipients: A case series and review of literature
P Ramanan, S Scherger, E Benamu… - Transplant Infectious …, 2020 - Wiley Online Library
The risk of toxoplasmosis in high‐risk cardiac transplant recipients is well recognized
prompting universal donor and candidate screening with administration of targeted post‐transplant …
prompting universal donor and candidate screening with administration of targeted post‐transplant …
Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network …
…, S Sillau, A Tagawa, S Scherger… - Therapeutic …, 2023 - journals.sagepub.com
Background: HIV-negative patients have substantial mortality from Pneumocystis jirovecii
pneumonia (PJP). We lack predictors of HIV-negative PJP-associated mortality. Objective: We …
pneumonia (PJP). We lack predictors of HIV-negative PJP-associated mortality. Objective: We …
Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents
…, KC Molina, JA Gutman, S Scherger… - Open Forum …, 2021 - academic.oup.com
Background The survival benefit of combination antifungal therapy for invasive mucormycosis
(IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT…
(IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT…
[HTML][HTML] Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?
L Shapiro, S Scherger, C Franco-Paredes… - Frontiers in …, 2023 - frontiersin.org
Introduction The European Medicines Agency (EMA) and the United States Food and Drug
Administration (FDA) announced conditions for using recombinant human interleukin-1 …
Administration (FDA) announced conditions for using recombinant human interleukin-1 …
Association between cytokine levels, sepsis severity and clinical outcomes in sepsis: a quantitative systematic review protocol
A Gharamti, O Samara, A Monzon, S Scherger… - BMJ open, 2021 - bmjopen.bmj.com
Introduction It is widely assumed that sepsis is a life-threatening systemic inflammation
caused by a dysregulated host response to infection mediated by an increase in multiple …
caused by a dysregulated host response to infection mediated by an increase in multiple …
[HTML][HTML] Progressive Encephalopathy With New Pulmonary Opacities in an Immunocompromised Host
M Orlov, AT Pham, D Merrick, M Wu, S Scherger… - CHEST Critical …, 2024 - Elsevier
Case Presentation A 48-year-old man with history of recent travel to central Mexico and
immunosuppression sought treatment with a 1-month-long history of progressive headache, …
immunosuppression sought treatment with a 1-month-long history of progressive headache, …
Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT)–an investigator-initiated single-arm …
M Krsak, S Scherger, MA Miller… - Therapeutic …, 2024 - journals.sagepub.com
Background: Severe gram-positive infections are frequent in people who inject drugs, and
successful completion of treatment presents unique challenges in this population. Objectives: …
successful completion of treatment presents unique challenges in this population. Objectives: …
